Roche launches a digital PCR system, a powerful new diagnostics platform in the fight against cancer and other diseases
- The Digital LightCycler System is a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient’s cancer, genetic disease or infection.
- The new system has the potential to find and quantify ultra-rare, hard to detect mutations, leading to early diagnosis and treatment strategies.
- The Digital LightCycler System is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in areas such as oncology and infectious diseases.
Basel, 23 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the Digital LightCyclerⓇ System, Roche’s first digital polymerase chain reaction ( PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods.
The Digital LightCycler System will allow clinical researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions. The system can then perform PCR and produce highly sophisticated data analysis on the results.
"Understanding the hidden characteristics of serious diseases is fundamental for ensuring that the most effective treatment is selected for each patient," said Thomas Schinecker, CEO of Roche Diagnostics. “The Digital LightCycler System will support clinical researchers and laboratories in identifying rare and emerging disease mutations. This can be instrumental in early diagnosis and therapy decisions."
For areas like oncology and infectious disease, the system provides new opportunities for researchers beyond what traditional PCR technology can achieve. This includes ultra rare targets, accurately quantifying how much of the target DNA or RNA there is at a molecular level, and other high precision analysis.
Roche has made significant contributions to establish and advance PCR technology over several decades. In 1991, Roche saw the potential in PCR and invested in refining the science for use in molecular diagnostics to detect pathogens and genetic code changes that lead to diseases.
The unique capabilities of the Digital LightCycler System complement the Roche suite of widely available PCR solutions. The launch of this new system adds to this PCR ecosystem, and builds on the company’s founding legacy in PCR. Both solutions will be offered by Roche, providing a suite of molecular solutions to the healthcare community.
The system will be available in 15 countries worldwide in 2022 with plans to launch into more countries in the near future. It will be CE-marked and has an FDA 510(k) exempt status.
About the Digital LightCyclerSystem
The Digital LightCycler System is the first digital PCR (dPCR) system from Roche and is intended for in-vitro diagnostic (IVD) testing. It performs absolute quantification of DNA and RNA targets using PCR technology. The Digital LightCycler System provides flexibility for laboratories through three unique reaction plates allowing customisation of the sample volumes used, the number of times a sample is partitioned (divided), and how many different tests can be run on a single sample (known as multiplexing). The system also features an easy workflow, moving from sample to results efficiently.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
|Hans Trees, PhD|
Phone: +41 61 687 41 47
Phone: +41 61 687 43 05
Phone: +41 61 682 28 31
Phone: +41 79 327 54 74
|Dr. Barbara von Schnurbein|
Phone: +41 61 687 89 67
Phone: +41 79 935 81 48
|Roche Investor Relations|
Dr. Bruno Eschli
Phone: +41 61 68-75284
Dr. Sabine Borngräber
Phone: +41 61 68-88027
|Dr. Birgit Masjost|
Phone: +41 61 68-84814
|Dr. Gerard Tobin|
Phone: +41 61 68-72942
|Investor Relations North America|
Phone: +1 650 225 3217
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
EMGA completes EUR 9.4M capital raise for Kashf Foundation with financing from BIO3.10.2022 02:00:00 CEST | Press release
LONDON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- The EURO 9.4 million funding facility for Kashf Foundation was originated, structured, and negotiated by Emerging Markets Global Advisory LLP (EMGA), the emerging market investment bank. Speaking on the transaction, Mr Shahzad Iqbal, CFO of Kashf Foundation said, “Kashf Foundation is registered as a Non-Banking Micro Finance Company regulated by the Securities and Exchange Commission of Pakistan. Set up in 1996 as the first specialized microfinance institution of Pakistan it began its operations as a Grameen replicator and since then, Kashf has successfully carved out a distinct and unique niche for itself in the microfinance sector in Pakistan by offering a suite of innovative and transformative products and services to low-income households especially for women. It has a current outreach of over 600,00+ female borrowers across its 360+ branches with a GLP of USD 90+ million.” “Just to share that it has always been a pleasure working with EMGA
FRO - 2022 Annual General Meeting30.9.2022 22:30:00 CEST | Press release
Frontline Ltd. (the “Company”) advises that the 2022 Annual General Meeting of the Shareholders of the Company was held on September 30, 2022 at 08:00 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2021 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorised to fill such vacancies as and when it deems fit. To re-elect John Fredriksen as a Director of the Company. To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Ola Lorentzon as a Director of the Company. To re-elect Ole B. Hjertaker as a Director of the Company. To re-elect Steen Jakobsen as a Director of the Company. To re-appoint PricewaterhouseCoopers AS of Oslo,
GOGL – 2022 AGM Results Notification30.9.2022 22:30:00 CEST | Press release
Golden Ocean Group Limited (the “Company”) advises that the 2022 Annual General Meeting of the Shareholders of the Company was held on September 30, 2022 at 08:30 a.m. at Par-la-Ville Place, 4th Floor, 14 Par-la-Ville Road, Hamilton Bermuda. The audited consolidated financial statements for the Company for the year ended December 31, 2021 were presented to the Meeting. In addition, the following resolutions were passed: To set the maximum number of Directors to be not more than eight. To resolve that vacancies in the number of Directors be designated as casual vacancies and that the Board of Directors be authorized to fill such vacancies as and when it deems fit. To re-elect John Fredriksen as a Director of the Company. To re-elect Ola Lorentzon as a Director of the Company. To re-elect James O’Shaughnessy as a Director of the Company. To re-elect Bjørn Tore Larsen as a Director of the Company. To re-elect Ben Mills as a Director of the Company. To re-appoint PricewaterhouseCoopers AS
Wolters Kluwer acquires Open Access publisher30.9.2022 20:45:00 CEST | Press release
Wolters Kluwer acquires Open Accesspublisher; Expands Breadth of Lippincott Journal Portfolio Waltham, MA, September 30, 2022 – Wolters Kluwer Health announced today that it has signed and completed an agreement to acquire IJS Publishing Group (IJSPG), a UK-based provider of peer-reviewed medical journals supporting scientists and authors. The IJSPG portfolio consists of 10 journal titles, including the International Journal of Surgery (IJS), IJS Case Reports (IJSCR), and Annals of Medicine and Surgery (AMS). IJSPG will become part of Health Learning, Research & Practice (LRP), which offers the Ovid®medical researchsolution, publishes over 300 medical journals and hundreds of medical and nursing books, and produces digital nursing solutions for education and practice. The acquisition expands the breadth and depth of the Lippincott journal portfolio with high impact factor, surgery-related research and strengthens its Open Access position with several well-established journals accessibl
EPH European Property Holdings PLC announces Interim Unaudited Results for the Six Months Ending 30 June 202230.9.2022 19:00:00 CEST | Press release
30 September 2022, Nicosia, Cyprus | Ad hoc announcement pursuant to Art. 53 LR EPH European Property Holdings PLC (EPH), a real estate investment company, today announces its interim unaudited results for the first half of 2022. BUSINESS HIGHLIGHTS FIRST HALF YEAR 2022 In February 2022, EPH European Property Holdings PLC (the “Company” or “EPH”) relocated to Cyprus, a member of the European Union and euro zone. Furthermore, EPH has changed its functional currency and presentation currency of EPH Group’s financial statements from US$ to EUR as of 1 January 2022. This takes into account the significant expansion of EPH’s European real estate portfolio and the strategy of the Company to focus its investments on major European cities. In addition, the change increases transparency and allows the Company to better reflect the performance of the asset portfolio, as a large proportion of the portfolio is located in Germany and Austria and rental income is generated in euros. EPH’s property p